Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGL | P35573 | 1/20 | 0.59 |
| ▸ | GBA2 | Q9HCG7 | 13/20 | 0.58 |
| ▸ | GAA | P10253 | 5/20 | 0.58 |
| ▸ | GBA1 | P04062 | 8/20 | 0.56 |
| ▸ | UGCG | Q16739 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22693211 | 0.95 | AGL (0.61) | AGLGBA2GAAGBA1UGCG | |
| SCHEMBL21349039 | 0.94 | GBA2 (0.66) | GBA2GAAGBA1UGCG | |
| SCHEMBL17243605 | 0.94 | GBA2 (0.66) | GBA2GAAGBA1UGCG | |
| SCHEMBL12909422 | 0.83 | GAA (0.66) | AGLGBA2GAAGBA1UGCG | |
| SCHEMBL12325137 | 0.83 | GAA (0.66) | AGLGBA2GAAGBA1UGCG | |
| SCHEMBL12289787 | 0.83 | GAA (0.66) | AGLGBA2GAAGBA1UGCG | |
| SCHEMBL17795750 | 0.83 | GAA (0.66) | AGLGBA2GAAGBA1UGCG | |
| Miglustat SCHEMBL9257713 | 0.81 | GBA2 (0.78) | AGLGBA2GAAGBA1UGCG | |
| SCHEMBL2268464 | 0.80 | AGL (0.72) | AGLGBA2GAAGBA1UGCG | |
| SCHEMBL8969835 | 0.80 | AGL (0.72) | AGLGBA2GAAGBA1UGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10842784-B2 | Treatment of energy utilization disease | VIDA PHARMA LIMITED (GB) | 2020-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10842784-B2 | Treatment of energy utilization disease | IRS1, SLC2A1, INSR | AGL 101/4885GBA2 508/4885GAA 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.